Results 191 to 200 of about 97,795 (300)

Impact of Metformin and Diabetes on Tumor Response to Total Neoadjuvant Therapy in Advanced Rectal Cancer: A Multicenter Retrospective Cohort Study

Asia-Pacific Journal of Clinical Oncology, EarlyView.
In advanced rectal cancer patients receiving total neoadjuvant therapy (TNT), overall tumor response did not differ by diabetes status or metformin use. However, among diabetic patients, metformin use was associated with higher overall complete response rates. These findings suggest a potential benefit of metformin in enhancing TNT response in diabetic
Sergei Bedrikovetski, Mahima Raju, Tracy Fitzsimmons, Ishraq Murshed, Timothy J. Price, Michael Penniment, Sudarsha Selva‐Nayagam, Tarik Sammour   +7 more
wiley   +1 more source

The Evolution of Neoadjuvant Treatment for Resectable Esophageal Squamous Cell Carcinoma: Past Achievements, Current Standards, and Future Perspectives. [PDF]

Cancers (Basel)
Ujiie N, Taniyama Y, Sato C, Okamoto H, Ozawa Y, Ishida H, Unno M, Kamei T.   +7 more
europepmc   +1 more source

Clinical Outcomes of the POPCORN Study: Pharmacodynamics of Pre‐Operative PD1 CheckpOint Blockade and Receptor Activator of NF‐κB Ligand (RANKL) Inhibition in Non‐Small Cell Lung Cancer (NSCLC)—A Phase 1B/2 Trial

Asia-Pacific Journal of Clinical Oncology, EarlyView.
Expanding on the growing evidence for neoadjuvant immunotherapy in resectable non‐small cell lung cancer, this study explored neoadjuvant nivolumab ± denosumab. Two of the 10 treated patients achieved a pathological complete response. CD8 T‐cell infiltration correlated with pathological response, warranting ongoing translational research to understand ...
Elizabeth Ahern, Cassie Turner, Rishendran Naidoo, David Godbolt, Amy Ives, Kirsten Popplewell, Zarnie Lwin, Sally Pearson, Kimberley Nelson, Jason Madore, William C Dougall, Brett G. M. Hughes   +11 more
wiley   +1 more source

Lung V5 and Planning Target Volume/Lung Volume Ratio as Independent Risk Factors for ≥Grade 2 Radiation Pneumonitis after Moderately Hypofractionated Radiotherapy: A Retrospective Study

Asia-Pacific Journal of Clinical Oncology, EarlyView.
Lung V5 and the planning target volume/lung volume ratio were identified as independent dosimetric risk factors for clinically significant radiation pneumonitis following moderately hypofractionated radiotherapy for lung cancer. Maintaining V5 < 35% may help mitigate this risk in clinical practice.
YuanYou Yang, FengXia Luo, Chao Wang, Gang Ren   +3 more
wiley   +1 more source

Evolving Trends in Laryngeal Cancer Mortality in the United States, 1999–2024: A Population‐Based Analysis With Subgroup Stratified Trends through 2020

Asia-Pacific Journal of Clinical Oncology, EarlyView.
Laryngeal cancer mortality in the United States declined from 1999 to 2016, followed by a plateau through 2024. Disparities persist, with males and NH‐Black populations experiencing disproportionately higher mortality. Continued regional and demographic differences highlight the need to strengthen prevention, early detection, and targeted public health
Aryan Tareen, Anoud Khan, Saqib Raza Khan, Muhammad Faez Tahir, Fatima Ibrahim Ahmed, Imaan Shoaib Mufti, Maryam Karam, Rija Tahir, Rinad Akhtar, Muntaha Irfan, Riham Zubair   +10 more
wiley   +1 more source

Nimotuzumab Combined With Chemoradiotherapy in Head and Neck Squamous Cell Carcinoma and Nasopharyngeal Carcinoma: A Systematic Review and Meta‐Analysis

Asia-Pacific Journal of Clinical Oncology, EarlyView.
This meta‐analysis of 18 studies (3962 patients) demonstrates that nimotuzumab combined with chemoradiotherapy significantly improves overall survival and progression‐free survival in locally advanced head and neck squamous cell carcinoma, without increasing severe toxicity.
Chengzheng Bao, Yue Zhang, Xiang Fei, Kaifeng Ji, Ming Jia, Zhijun Li, Chao Bian   +6 more
wiley   +1 more source

Induction Chemoimmunotherapy Versus Induction Chemotherapy Followed by Concurrent Chemoradiotherapy for Locally Advanced Esophageal Squamous Cell Carcinoma: A Propensity Score-Matched Study. [PDF]

J Clin Med
Liu J, Deng W, Dong X, Zhao Y, Jiang L, Long L, Teng Y, Yang D, Yu J, Chang X, Yu H, Shi A, Wang W, Yu R.   +13 more
europepmc   +1 more source

Australian Practical Guide on the Management of Muscle‐Invasive Bladder Cancer

Asia-Pacific Journal of Clinical Oncology, EarlyView.
Australia's management of muscle‐invasive bladder cancer is evolving, with increased use of perioperative therapy and emerging immunotherapies. However, challenges such as cisplatin ineligibility, limited access, and costs persist. Expanding bladder‐sparing approaches, precision medicine, and integrated care pathways will be key to improving outcomes ...
Dickon Hayne, Shomik Sengupta, Alison Y. Zhang, Niara Oliveira, Manish I. Patel, Ian Vela, Ian D. Davis   +6 more
wiley   +1 more source

Low-intensity induction chemotherapy before chemoradiotherapy for rectal cancer: 10-year overall survival in the LARC-RRP trial. [PDF]

Br J Radiol
Ree AH, Meltzer S, Flatmark K, Dueland S.   +3 more
europepmc   +1 more source

Seven Years of Watch and Wait With Rectal Cancer—Reflections and Optimisations

ANZ Journal of Surgery, EarlyView.
ABSTRACT Purpose Sir Charles Gairdner Hospital (SCGH) commenced an observation strategy in patients with a complete clinical response, Watch and Wait (W&W), for rectal adenocarcinoma in 2017 using a rigorous surveillance protocol. Our earlier results (2017–2019) have been published.
Ben Finlay, Emma Powell, Anne Long, Rohen White, John Herron, Michael Warner   +5 more
wiley   +1 more source